Aurinia Pharmaceuticals Inc. Stock price

Equities

AUPH

CA05156V1022

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
5.01 USD +0.20% Intraday chart for Aurinia Pharmaceuticals Inc. -2.53% -44.27%
Sales 2024 * 223M Sales 2025 * 288M Capitalization 723M
Net income 2024 * -6M Net income 2025 * 58M EV / Sales 2024 * 1.7 x
Net cash position 2024 * 344M Net cash position 2025 * 390M EV / Sales 2025 * 1.16 x
P/E ratio 2024 *
-91.1 x
P/E ratio 2025 *
12.7 x
Employees 300
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.20%
1 week-2.53%
Current month-12.41%
1 month-16.78%
3 months-46.07%
6 months-37.22%
Current year-44.27%
More quotes
1 week
4.85
Extreme 4.85
5.07
1 month
4.85
Extreme 4.85
6.02
Current year
4.85
Extreme 4.85
9.43
1 year
4.85
Extreme 4.85
12.43
3 years
4.07
Extreme 4.07
33.97
5 years
3.52
Extreme 3.52
33.97
10 years
1.41
Extreme 1.41
33.97
More quotes
Managers TitleAgeSince
Founder 52 93-06-15
Chief Executive Officer 54 19-04-28
Founder 65 93-06-15
Members of the board TitleAgeSince
Founder 65 93-06-15
Director/Board Member 73 19-06-25
Chief Executive Officer 54 19-04-28
More insiders
Date Price Change Volume
24-03-28 5.01 +0.20% 1,374,533
24-03-27 5 +1.42% 1,438,779
24-03-26 4.93 -1.20% 948,678
24-03-25 4.99 +0.40% 969,097
24-03-22 4.97 -0.80% 1,792,314

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
5.01 USD
Average target price
10.57 USD
Spread / Average Target
+111.01%
Consensus
  1. Stock
  2. Equities
  3. Stock Aurinia Pharmaceuticals Inc. - Nasdaq